P110α
信号转导衔接蛋白
蛋白质亚单位
SH2域
原癌基因酪氨酸蛋白激酶Src
突变体
同源建模
蛋白激酶结构域
突变
细胞生物学
结合位点
激酶
磷酸化
生物
遗传学
基因
酶
生物化学
作者
Nabil Miled,Ying Yan,Wai-Ching Hon,Olga Perišić,Marketa Zvelebil,Yuval Inbar,Dina Schneidman‐Duhovny,Haim J. Wolfson,Jonathan Backer,Roger Williams
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2007-07-12
卷期号:317 (5835): 239-242
被引量:380
标识
DOI:10.1126/science.1135394
摘要
Many human cancers involve up-regulation of the phosphoinositide 3-kinase PI3Kα, with oncogenic mutations identified in both the p110α catalytic and the p85α regulatory subunits. We used crystallographic and biochemical approaches to gain insight into activating mutations in two noncatalytic p110α domains—the adaptor-binding and the helical domains. A structure of the adaptor-binding domain of p110α in a complex with the p85α inter–Src homology 2 (inter-SH2) domain shows that oncogenic mutations in the adaptor-binding domain are not at the inter-SH2 interface but in a polar surface patch that is a plausible docking site for other domains in the holo p110/p85 complex. We also examined helical domain mutations and found that the Glu 545 to Lys 545 (E545K) oncogenic mutant disrupts an inhibitory charge-charge interaction with the p85 N-terminal SH2 domain. These studies extend our understanding of the architecture of PI3Ks and provide insight into how two classes of mutations that cause a gain in function can lead to cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI